CORT: Corcept Therapeutics Incorporated Twitter on Stock

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 3, 6:50 AM Corcept Therapeutics (CORT): Q1 EPS of -$0.10 misses by $0.01. Revenue of $1.72M misses by $0.76M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 7, 5:23 PM More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue side. Net profit declined Y/Y, as the drug developer racked up higher SG&A expenses due to increased staffing, consultancy and other professional services costs related to the rollout of Korlym. Comment! [Healthcare, Earnings]
Thursday, March 7, 5:17 PM Corcept Therapeutics (CORT): Q4 EPS of -$0.09 in-line. Revenue of $1.4M misses by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 4, 4:05 PM Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an upgrade yesterday by Piper Jaffray and analysts at Janney Capital beginning coverage of the stock with a Buy rating and a $3 price target. CORT climbed just over 10% on Thursday to close at $1.63 a share, its best finish since early November. Comment! [Healthcare, On the Move]
Tuesday, December 4, 2012, 12:45 PM Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move]
Tuesday, August 7, 2012, 9:10 AM Premarket gainers: USHS +37%. BSFT +24%. FOSL +21%. LOPE +18%. BVSN +10%. ZLCS +10%. VRNG +9%. IHG +8%. CIM +6%. NOK +6%. MGM +5%. DCTH +5%.
Losers: WMS -20%. LEAP -18%. NIHD -16%. ELN -11%. CORT -10%. HEK -9%. DUF -8%. Comment! [On the Move]
Monday, July 2, 2012, 9:10 AM Premarket gainers: CELL +64%. LNCR +21%. AMPE +17%. ATPG +13%. WFR +9%. AMLN +9%. MU +7%.
Losers: ANH -6%. OREX -5%. CORT -5%. Comment! [On the Move]
Monday, July 2, 2012, 8:38 AM Corcept Therapeutics (CORT) intends to sell 11M shares to raise funds for R&D and other purposes. Corcept develops drugs for severe psychiatric and metabolic disorders, including Cushing's syndrome and psychotic depression. Shares -5.35% premarket. (PR) Comment! [Healthcare, On the Move]
Friday, June 29, 2012, 12:41 PM ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning: Navidea (NAVB +3.7%), BioMarin (BMRN +4.5%), Corcept Therapeutics (CORT +4%), Medivation (MDVN +5.2%), Amicus Theraputics (FOLD +2%), Raptor Pharmaceuticals (RPTP +0.2%), Synageva BioPharma (GEVA +3.2%), Aegerion (GEVA +3.7%). Comment! [Healthcare, On the Move]
Thursday, March 22, 2012, 11:01 AM Leerink Swann says the pricing for Corcept's (CORT -0.8%) Korlym is higher than expected at $186 per 300mg tablet, which should help offset its caution regarding patient numbers. The drug developer announced this morning it will begin shipping Korlym starting April 11. 1 Comment [Healthcare]
Tuesday, February 21, 2012, 9:07 AM Premarket gainers: CORT +61%. THLD +59%. PBH +24%. CTIC +11%. CHG +10%. STM +8%. SWC +8%. JASO +7%. WYNN +6%. IVAN +6%. SSN +5%. YGE +5%. HL +4%. IRE +4%. TSL +4%. FRO +3%. M +3%. HD +3%. DANG +3%. CS +3%. STP +3%. NG +3%.
Losers: GTXI -39%. CHTP -13%. WFT -11%. CTRP -9%. CIE -5%. NBG -5%. RIG -5%. CIEN -4%. WMT -3%. Comment! [On the Move]
Tuesday, February 21, 2012, 6:56 AM Corcept Therapeutics (CORT) continues to skyrocket after landing FDA approval for its Korlym oral medicine used to treat Cushing's syndrome patients. The firm expects to launch of Korlym within the next two to three months, with consensus sales forecasts for the drug running as high as $409M by 2016. Shares +68.1% premarket. Comment! [On the Move, Healthcare]
Friday, February 17, 2012, 4:45 PM Corcept Therapeutics (CORT), a specialty drug company that hasn’t generated revenue since 2009, wins FDA approval for its Korlym treatment that uses the active ingredient of the abortion pill RU-486 to treat Cushing’s Syndrome. Shares +42.5% after a trading halt. Comment! [Healthcare, On the Move]
Thursday, June 30, 2011, 11:56 AM Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively. Comment! [On the Move, Healthcare]
Monday, June 6, 2011, 8:53 AM A massive data dump this morning and over the weekend from biotech firms reporting results from various drug trials and regulatory updates. Stocks on the move as a result: Cell Therapeutics (CTICD, press release) +2.8%, Exelixis (EXEL, PR) -2.2%, Incyte (INCY, PR) +3%, Corcept Therapeutics (CORT, PR) -4.8%, United Therapeutics (UTHR, PR) -6.1%, RXi Pharmaceuticals (RXII, PR) +17.7%, Impax Labs (IPXL, PR) -3.3%. Comment! [Healthcare, On the Move]

CORT Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated